Arcadia Biosciences, Inc. (RKDA)
$
4.6
-0.18 (-3.91%)
Key metrics
Financial statements
Free cash flow per share
-5.8621
Market cap
5.7 Million
Price to sales ratio
1.0814
Debt to equity
0.0024
Current ratio
3.9919
Income quality
2.8816
Average inventory
1.1 Million
ROE
-0.2172
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Arcadia Biosciences, Inc. produces and markets plant-based health and wellness products in the United States. The company achieved a revenue of $5,045,000.00 indicating its niche market focus. Additionally, the EBITDA ratio is -1.49 highlighting the company's operational efficiency. The gross profit stands at $2,082,000.00 underscoring the company's profitability from core operations. Furthermore, the weighted average number of shares outstanding is 1,363,303.00 highlighting the company's shareholder base. The operating expenses amount to $5,730,000.00 encompassing various operational costs incurred. Engaging in research and development, Arcadia focuses on enhancing crop performance, particularly in wheat, to improve farm economics and the viability of crops for diverse applications including food ingredients and industrial uses. Incorporated in 2002, the company is headquartered in Davis, California, and is dedicated to driving advancements in agricultural productivity and healthful product offerings. The stock is affordable at $4.60 making it suitable for budget-conscious investors. It enjoys a high average trading volume of 10,570.00 indicating strong liquidity. With a market capitalization of $6,288,384.00 the company is classified as a small-cap player. Arcadia Biosciences is a key player in the Agricultural Inputs industry, contributing significantly to the overall market landscape. It belongs to the Basic Materials sector, driving innovation and growth. As a company committed to improving agricultural practices and developing value-added health products, Arcadia is well-positioned to continue influencing its market segment positively while catering to the needs of health-conscious consumers.
Is Arcadia Biosciences, Inc. (RKDA) a good investment?
Investing in Arcadia Biosciences, Inc. (RKDA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Arcadia Biosciences, Inc. (RKDA)'s stock forecast?
Analysts predict Arcadia Biosciences, Inc. stock to fluctuate between $2.40 (low) and $10.31 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Arcadia Biosciences, Inc.'s market capitalization?
As of 2025-05-29, Arcadia Biosciences, Inc.'s market cap is $6,288,384, based on 1,367,040 outstanding shares.
How does Arcadia Biosciences, Inc. compare to competitors like The Sherwin-Williams Company?
Compared to The Sherwin-Williams Company, Arcadia Biosciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Arcadia Biosciences, Inc. (RKDA) stock?
To buy Arcadia Biosciences, Inc. (RKDA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for RKDA. Place an order (Market, Limit, etc.).
What is the best time to invest in Arcadia Biosciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Arcadia Biosciences, Inc. stock ever split?
Arcadia Biosciences, Inc.'s last stock split was 1:40 on 2023-03-01.
How did Arcadia Biosciences, Inc. perform in the last earnings report?
Revenue: $5,045,000 | EPS: -$5.16 | Growth: -54.34%.
Where can I find Arcadia Biosciences, Inc.'s investor relations reports?
Visit https://www.arcadiabio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Arcadia Biosciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Arcadia Biosciences, Inc. stock?
All-time high: $255.74 (2021-02-11) | All-time low: $1.85 (2024-04-15).
What are the key trends affecting Arcadia Biosciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
19 days ago
Arcadia Biosciences, Inc. (NASDAQ:RKDA ) Q1 2025 Earnings Conference Call May 8, 2025 2:00 PM ET Company Participants Mark Kawakami - Chief Financial Officer T.J. Schaefer - President and Chief Executive Officer Conference Call Participants Ben Klee - Lake Street Operator Hello, and welcome to Arcadia Biosciences First Quarter 2025 Financial Results and Business Highlights Conference Call.
globenewswire.com
22 days ago
-- Revenues increase 22% year over year driven by 90% growth in Zola ® -- -- Arcadia sells patents for $750K and eliminates $1M in liabilities -- -- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc .® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2025.
globenewswire.com
a month ago
Arcadia Biosciences, Inc.® (Nasdaq: RKDA) will release its financial and business results for the first quarter of 2025 on May 8, 2025 at 2:00 p.m. ET.
seekingalpha.com
2 months ago
Arcadia Biosciences, Inc (NASDAQ:RKDA ) Q4 2024 Results Conference Call March 20, 2025 4:30 PM ET Company Participants Mark Kawakami - Chief Financial Officer T.J. Schaefer - President & Chief Executive Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Operator Good afternoon, and welcome to Arcadia Biosciences Fourth Quarter and Full Year 2024 Financial Results and Business Highlights Conference Call.
businesswire.com
2 months ago
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2024. “We are extremely pleased with the progress we made in 2024, particularly in the second half of the year following the sale of our GoodWheat™ assets,” said T.J. Schaefer, president and CEO. “Our focus on Zola® coconut water led to 80 percent revenue grow.
businesswire.com
3 months ago
DALLAS--(BUSINESS WIRE)--Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the fourth quarter and full year of 2024 after market close on March 20, 2025. The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss fourth-quarter and year-end results and key strategic achievements. Interested participa.
businesswire.com
3 months ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Arcadia Biosciences, Inc. (NASDAQ: RKDA) and Roosevelt Resources LP is fair to Arcadia shareholders. Upon closing of the proposed transaction, Arcadia shareholders are expected to own approximately 10% of the combined company. Halper Sadeh encourages Arcadia shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212.
businesswire.com
6 months ago
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Arcadia Biosciences, Inc. (NasdaqCM: RKDA) and Roosevelt Resources LP. Pursuant to the terms of the agreement, upon completion of the Merger, Arcadia stockholders are expected to own approximately 10% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are a.
zacks.com
6 months ago
RKDA inks deal with Roosevelt to become a new entity, Roosevelt Resources, with Roosevelt as the majority shareholder.
prnewswire.com
6 months ago
NEW YORK , Dec. 6, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Arcadia Biosciences, Inc. (NASDAQ: RKDA ), relating to the proposed merger with Roosevelt Resources LP.
See all news
